ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs for patients with inflammatory or kidney diseases with high unmet medical needs. For inflammatory diseases, ZyVersa is developing a highly differentiated inflammasome ASC inhibitor (IC 100), and in kidney disease, a novel phase 2a-ready cholesterol efflux mediator (VAR 200). Multiple indications are being explored in both therapeutic areas.
Ticker:
ZVSA
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Multiple Therapeutics
Lead Product in Development:
VAR 200 Cholesterol Efflux Mediator for Renal Diseases
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Two
Speaker
